Question: Sow is keen to impress at MK Dons

Represent the article to find a fitting news title.

Osman Sow is looking to make a name for himself in English football after signing for MK Dons.
The striker, Robbie Neilson's number one target this summer, put pen to paper on a two-year deal at Stadium MK on Monday night.
Having worked for the manager in Scotland, where he scored 23 goals in 52 appearances for Hearts before securing a move to the Chinese Super League, Sow said he was keen to come to England and ply his trade.
“I’m very happy and I’m looking forward to getting going," he told iFollow MK Dons.
“Robbie spoke very highly of the club and it’s a big opportunity for me to come back to England, which is the best country in the world to play football in.
“I like to create chances and I like to score goals but, for me, the big thing is winning football games – I want to win and that’s what makes me sleep well at night!”

The video will start in 8 Cancel
Get Aston Villa FC updates directly to your inbox + Subscribe Thank you for subscribing! Could not subscribe, try again later Invalid Email
It's a cracker
Aston Villa midfielder Josh Onomah will have left Steve Bruce rubbing his hands with glee after scoring a stunning goal for England Under 21s against Scotland last night.
Onomah, on a season-long loan from Tottenham Hotspur, broke the deadlock in Middlesbrough with a goal of pure beauty.
Jordan wanted
Marseille are willing to pay Aston Villa just shy of £9m for Jordan Amavi in a permanent deal next summer, according to reports abroad.
Left-back Amavi headed back to his native France in July and has enjoyed a successful start in Ligue 1 - L’OM are third in the league behind Paris Saint-Germain and Monaco and won their opening Europa League match against Konyaspor.
Strict diet
When Tony Daley turns 50 later this month he’ll reward himself with a rare day off.
“On my birthday I will be smashed!” he laughed.
First impressions
Scott Hogan has admitted that he hasn’t met too many sharper individuals in football than Republic of Ireland and former Aston Villa assistant boss Roy Keane.
Hogan, who is preparing for tonight’s crucial World Cup qualifying encounter against Moldova at the Aviva Stadium, has hooked up with the Ireland squad for the first time in his career, after missing out previously with long-term injuries.
Winning start
Aston Villa striker Ross McCormack got off to a winning start in his first game for Melbourne City.
McCormack made his debut as Melbourne kicked off their A-League campaign with a 2-0 victory over Brisbane Roar in front of a crowd of 9,589 at AAMI Park.
Teacher's pet
Ahmed Elmohamady has been described as a ‘manager’s dream’ by the man who has now recruited him THREE times.
Villa boss Steve Bruce swooped to sign the 30-year-old from his former club Hull City this summer and it’s a move he’s glad he pursued.
Predictions time
I hate to say I told you so. But I told you so!
At the start of September I predicted Villa would remain unbeaten throughout the month, picking up 14 points along the way.
Lee's on top
Step aside Steve Bruce, you were beaten by the better candidate this time out.
Not that the Villa boss will mind missing out on September’s Manager of the Month gong.


Question: Represent this title to get a news article that provides more details about it.

Question: Kitty litter helps Wyoming bentonite past drilling slump

Represent this text to find a news title for it

5:48 Dave Barry's 2016 Holiday Gift Guide Pause
1:20 The United States of Powerball
57:11 Dave Barry and Carl Hiaasen talk politics, Florida and a presidential bid at the Miracle Theatre
1:38 Dave Barry goes searching for protesters on the campaign trail
1:28 The day Cassius Clay and The Beatles shared the ring
2:27 Dave Barry discovers something other than fish in the ocean off Rio
0:47 Dolphins CB Lippet talks about hit that sidelined him
0:36 Dolphins' Matt Moore focused for playoffs
0:55 Dolphins' Landry talks loss to New England

This news article should be represented to find a fitting news title

MID continues releasing water from McClure
Officials get aerial view of Merced County flooding
Fire leads Merced deputies to marijuana grow
Tempers flare in Marysville traffic
Search for Ghost Ship warehouse fire victims continues in Oakland
Farmers 'fed up' with state water grab
0:49


Question: represent the title to find an explanatory news article

Question: Mohanlal's Toned-down Avatar Is The Talk Of The Social Media!

represent this text to find a news title for it

It has been over 50 days since we saw Mohanlal making a public appearance. Reportedly, the actor was undergoing an intense training to shed a few kilos for his upcoming film Odiyan, directed by VA Shrikumar Menon.
According to the reports, Mohanlal underwent a special training under the guidance of a group of trainers, yoga masters, and masseurs from France. The fans of the actor and the entire Malayalam film audiences have been eagerly waiting to see the new avatar of Mohanlal.
It was then that VA Shrikumar Menon came up with an announcement regarding the launch of the next teaser of Odiyan and also the unveiling of the new look of Mohanlal. This announcement further raised the expectations of all the fans of Mohanlal..

represent the article to find a fitting news title

Katrina Kaif’s No Make Up Look Will Make You Ditch Your Make Up Kit Right Now! (View Pics)


Question: I found this news title. Can you represent it to find an explanatory news article?

Question: PHOTOS: At Westminster, Rumor Wins - But They're All Good Dogs

There was no end of intrigue at the Westminster Kennel Club Dog Show this year.
Rumor, the German shepherd who narrowly lost at last year's show, had come close to simply hanging up her leash and retiring. Instead, she stormed back to win her category again this year — and then, to top it all off, beat out more than 2,800 dogs to take Best in Show on Tuesday, as well.
The triumph makes her only the second German shepherd to win the top prize in Westminster's 141-year history. Considering Westminster is the second-longest continuously running sporting event in the U.S. — second only to the Kentucky Derby — the redemptive win for the 5 1/2-year-old female is no mean feat.
Not only that, but as NPR's Merrit Kennedy noted earlier this month, Westminster also played host to another rarity at this year's dog show: cats. The featured felines shared a showcase with the dogs called Meet & Compete.
Still, whatever words we can offer on the event seem a little beside the point. The dogs — big and small, noble and loony — are the main event.
So, without further throat-clearing, here's what you came for: A few of our very favorite images from the competition.

HERE'S THE RUNDOWN: Charlie Murphy: His Final Days Kendall Jenner Back In Action After Pepsi Fiasco Survivor: Trans Contestant Outed On Show Kelly Rowland Ambushed By Protestors
Start the conversation, or Read more at TMZ.com.


Question: Represent the title to find an explanatory news article!

Question: Liberals on track for $4B deficit

TORONTO -
Ontario’s fiscal watchdog says the Liberal government will run a deficit this fiscal year, despite claims it has balanced the budget.
In a new report Monday, the Financial Accountability Office said the Liberals will run a $4 billion deficit in 2017-2018, and will continue to be in the red over the next few years.
More moderate growth in revenues and the increasing fiscal impact of the province’s Fair Hydro Plan, which cuts electricity rates by 25 per cent, will take their toll on Ontario’s books the report notes. It also says a long-simmering accounting dispute between the Liberal government and Auditor General Bonnie Lysyk over how to count two public sector pension plans on the ledger is contributing to uncertainty.
“We’ve been very consistent that because of a number of factors we think the deficit will re-emerge,” said FAO chief economist David West. “Now, with this accounting debate it will become more significant.”
The Liberals presented a balanced budget in the spring, a year ahead of the provincial election, and have promised to keep the books in balance through the next couple of years.The FAO, however, projects the government’s budget deficit will grow to $9.8 billion in 2021-2022.
“The government is out borrowing this money,” West said. “This current year they’re going to borrow $23 billion in the markets. That’s going to rise to $45 billion in the coming years.”
The FAO also said the government’s new hydro plan will add $3.2 billion to the budget deficit by 2021-2022.
Last year Lysyk questioned the province’s decision to include a pair of public pensions — the Ontario Public Service Employee’s Union Pension Plan and the Ontario Teacher’s Pension Plan — as assets on its balance sheet.
The FAO said in its report that since the government has not adopted the auditor’s recommended accounting for both the pension assets, and with the addition of the Fair Hydro Plan, it is becoming more difficult for legislators and the public to assess the government’s fiscal projections.

Goodbye, 2016. You were a leap year, and over your 366 days, the world developed a taste for leaps into the unknown. The improbable beat the odds, time and again.
Poll after poll said that Donald Trump had almost no chance of winning the U.S presidential election; he’s now the president-elect. Poll after poll said Britons would narrowly vote to remain in the European Union; they voted narrowly for Brexit.
2016 was a very bad year to be a professional prognosticator.
So, what do the next 12 months have in store?
The Globe and Mail editorial board’s crack team of oddsmakers is once again ready to make book on the likelihood of various events occurring in 2017.
Let’s begin in OTTAWA.
Probability of a change in government: 0 per cent
Probability of the Trudeau government introducing legislation to reform political fundraising rules: 63 per cent
Probability of the government introducing legislation to hold a referendum on electoral reform: 23 per cent
Probability of major electoral reform: 23 per cent
Probability of minor cabinet changes: 78 per cent
Probability of a major cabinet shuffle: 17 per cent
INTERNATIONAL AFFAIRS
Probability that Canadian special forces will still be in Iraq at the end of 2017: 75 per cent
Odds that the government will refer to their mission, which has often involved combat, as a “combat mission”: 12 per cent
Probability of Canada sending a significant number of troops to serve in a “peace” mission in Africa: 88 per cent
Odds that the mission will look more like the Iraq or Afghanistan missions, and less like traditional peacekeeping: 100 per cent
THE WORLD
Probability that Bashar al-Assad will still be President of Syria at the end of the year: 79 per cent
Probability that the so-called Islamic State will control less territory at the end of the year than at the beginning: 73 per cent
Probability that Angela Merkel will be re-elected as German Chancellor: 72 per cent
Odds of National Front leader Marine Le Pen winning the French presidential election: 29 per cent
Probability that British Prime Minister Theresa May will begin the formal Brexit process by her self-imposed deadline of March: 38 per cent
By the end of the year: 68 per cent
Probability that President Donald Trump will call for the renegotiation of NAFTA: 82 per cent
That he will approve the Keystone XL pipeline: 93 per cent
Probability of increased tensions between Washington and Beijing: 90 per cent
Probability that the relationship between Mr. Trump and Vladimir Putin will be worse at the end of the year than at the beginning: 80 per cent
THE ECONOMY
Probability that the Bank of Canada will raise its benchmark interest rate in the first half of 2017: 6 per cent
In the second half of the year: 26 per cent
Odds of the U.S. Federal Reserve raising interest rates in the first half of the year: 64 per cent
In the second half of the year: 34 per cent
Probability that the Canadian dollar will finish the year higher versus the U.S. dollar: 19 per cent
Odds that the Canadian unemployment rate will finish the year higher than at the start: 49 per cent
Probability that the West Texas Intermediate oil price will end the year above US$50: 41 per cent
INVESTING
In 2015, the S&P/TSX Composite index was one of the world’s worst-performing major stock indexes, but in 2016 it bounced back and was a top-performing major index.
Probability of the S&P/TSX composite index ending the year higher: 38 per cent
Of the S&P/TSX outperforming the S&P 500: 47 per cent
SPORTS
Odds of a Canadian team winning the NBA title: 7 per cent
Of a Canadian team winning the World Series: 14 per cent
Of a Canadian team winning the Stanley Cup: 28 per cent
Of a Canadian being the NHL’s leading point-getter: 67 per cent
Probability of a Canadian being the top goal-scorer: 51 per cent
Probability of the NHL reaching a deal to send players to the Winter Olympics in February, 2018: 35 per cent
Probability of an eighth NHL team coming to Canada in 2017: Same as the odds of a change in government in Ottawa.
Report Typo/Error


Question: ’60s Scoop deal to compensate victims, fund reconciliation foundation

this news article should be represented to find a fitting news title

Chief Marcia Brown Martel sings outside the parliament buildings following a government news conference announcing a compensation package for indigenous victims of the sixties scoop, in Ottawa on Friday, October 6, 2017. (Adrian Wyld/The Canadian Press)
Survivors of a period in the 1960s that saw Indigenous children taken from their homes and placed with non-Indigenous families hope an agreement in principle with the federal government will put a stop to Aboriginal children being stolen from their language, culture and identity.
Beaverhouse First Nation Chief Marcia Brown Martel, who was herself placed in the foster system as a child only to suffer emotional, physical and sexual abuse, said she has “great hope” now that a deal has been reached including $750 million in compensation for victims.
In February, the Ontario Superior Court found the government liable for the harm caused by the ’60s Scoop. Brown Martel was the representative plaintiff.
“I have great hope that because we’ve reached this plateau that this again will never, ever happen in Canada again,” Brown Martel said Friday as she stood beside Crown-Indigenous Affairs Minister Carolyn Bennett on Parliament Hill for the announcement on the settlement deal.
At the same time, she warned, Indigenous children are still subject to the “millennium scoop.”
“Children are still within the child welfare system,” she said
“They call it ‘in care’ but it adds a risk factor for them. Therefore, one must stop using that term … they’re not in care. They’re away from their communities … our children need to come home.”
Bennett fought back tears Friday as she announced details of the deal with Brown Martel and other survivors — a package that also includes up to $50 million for a foundation for healing and reconciliation.
The federal government has also earmarked $75 million for legal fees. The compensation money will go to individuals classified as status Indians and Inuit.
The ’60s Scoop a dark and painful chapter in Canada’s history, Bennett said.
“Their stories are heartbreaking,” Bennett said. “They talked of their identity being stolen. They talked about not really feeling that you belong anywhere because people have been moved so often or that they didn’t really have a home.”
Too many Indigenous children are still being taken from their families, she added, insisting Ottawa must change the current design of the system to ensure funding goes toward children, family and communities rather than lawyers, agencies and non-Indigenous foster families.
“We want that overhaul to happen so that we a system of the rights and well-being of Indigenous children and youth to be raised in their language and culture and not have this harm done that was done to these courageous people,” she said.
The agreement is a ”first step” in resolving ’60s Scoop litigation, Bennett added, noting the federal government is committed to working with other Indigenous Peoples affected.
The provinces and territories are also working on resolving remaining litigation, she said, adding individual compensation will be determined among legal counsel.
The agreement in principle announced by the government is less than the $1.3 billion Brown Martel sought for victims of the Ontario Scoop in which at-risk on-reserve Indigenous children were placed in non-Aboriginal homes from 1965 to 1984 under terms of a federal-provincial agreement.
In a class action started in 2009, Brown Martel maintained the government had been negligent in protecting her and about 16,000 other on-reserve children from the lasting harm suffered from being alienated from their heritage.
Jeffery Wilson, one of her lawyers, said previously the class action was the first anywhere to recognize the importance of a person’s cultural heritage and the individual harm caused when it is lost.
With files from Colin Perkel
Kristy Kirkup, The Canadian Press

Nishnawbe Aski Nation is calling a Canadian Human Rights Tribunal ruling “a huge win for children.”
The CHRT released their 101-page decision Thursday. In January 2016, the tribunal ruled that Canada discriminated against 163,000 Indigenous children by not providing enough funding for child and family services on reserve.
Its most recent finding, the result of a compliance hearing in March 2017, stated the government will be held accountable for that discrimination, and also for its attempts to justify its inaction.
This marks the fourth time the tribunal said Canada was not fully complying with the 2016 order.
NAN Grand Chief Alvin Fiddler said the tribunal is breaking new ground.
“The good news is that Canada is responding to this challenge and is working in collaboration ... to develop solutions,” said Fiddler.
“Canada's attempted justification for its inaction in the wake o a 2016 finding of discrimination by the Human Rights Tribunal has been flatly rejected as the Panel recognized that Canada's 'business as usual' approach was a conscious choice to perpetuate discrimination.”
Fiddler added, “This is a huge win for our children.”
Canada is now required to report according to a schedule on their ongoing compliance, as well as fund the actual costs agencies face providing full and equitable services.
The tribunal panel stated it was “incorrect for Canada to say it did everything it could and everything that was asked of it.”
“This case is vital because it deals with mass removal of children,” said the tribunal. “There is urgency to act and prioritize the elimination of the removal of children from their families and communities.”
Indigenous children represent seven per cent of all kids under the age of 15, but make up more than half of all kids in foster care. In some provinces, that figure is closer to 90%, including Metis and Inuit children.
Deputy Grand Chief Anna Betty Achneepineskum holds the social service portfolio for NAN.
“The importance of this ruling it its recognition that children come first and that bureaucratic inaction, no matter how well-intentioned, can perpetuate discrimination,” said Achneepineskum.
“The Tribunal has effectively created a cost of inaction and has ordered Canada to compensate parties involved dating back to its ruling in 2016.”
Indigenous Services Minister Jane Philpott said Thursday child welfare agencies on reserves will immediately start getting funding to cover the actual cost of program.
NDP Indigenous Critic and Timmins-James Bay MP Charlie Angus said he's concerned there isn't a dollar figure attached to the promise. Philpott said they are still sorting out what this will cost and that the money will be in the 2018 federal budget.
Angus said it's worrying that government doesn't know what it has to spend. He said a recent report on the funding shortfall in Manitoba alone was $80 million a year, which would mean the shortfall nationally is likely at least $200 million.
- With files from The Canadian Press


Question:
i found this news title. can you represent it to find an explanatory news article?
E.g. '['Represent this title to get a news article that provides more details about it', 'Border-tax plan would cut growth: study']' == '['Represent this text to find a news title for it', 'OTTAWA -\nA proposed U.S. border-adjustment tax that has stirred up fears in Corporate Canada would inflict considerable damage on both economies, a new report said Tuesday.\nThe study was released a day after Prime Minister Justin Trudeau met President Donald Trump and top House lawmaker Paul Ryan, who has promoted the border-tax measure.\nThe analysis by the C.D. Howe Institute think tank estimated the U.S. policy change would shave nearly a full percentage point from Canada’s economic growth.\nThe study’s authors said the plan would reduce bilateral trade in both directions and predicted it would cut nearly 1.3 percentage points from U.S. economic growth.\n“It is trade-distorting and economically damaging to the United States and its trading partners,” co-authors Dan Ciuriak and Jingliang Xiao wrote about the border-tax proposal.\n“Canada is heavily exposed to the ramifications of a (border-adjustment tax).”\nIt’s unclear whether Trudeau was able to get some clarity — or reassurance — from Ryan on the future of the border tax, which has Canadian firms deeply concerned.\nWhen asked whether Trudeau learned more about the border-tax proposal, a spokeswoman in his office pointed to a statement that only said the prime minister discussed trade during his meeting with Ryan.\nForeign Affairs Minister Chrystia Freeland said Tuesday that the meetings in Washington confirmed her expectations the fate of the border-tax plan was uncertain.\n“This is very much in the early stages and there is a very broad diversity of opinion in the United States around that,” Freeland told reporters in Ottawa.\n“It’s not appropriate for us to have a position on that until we see where the U.S. lands.”\nShe noted that the border-tax measure is part of a broader tax-reform plan.\nFreeland also said talks surrounding the renegotiation of the North American Free Trade Agreement had yet to begin because appointees for the new U.S. secretary of commerce and trade representative positions still had to be confirmed.\n“Therefore, it’s not possible for us to start the negotiations at a technical level and we haven’t started,” she said.\n“Yesterday’s conversation with the president was very productive. It’s a good start.”']' != '['Represent the article to find a fitting news title:', 'Former Treasury Secretary Jacob Lew provides his thoughts on the turnaround in the economy and recent tax cuts passed by Congress.']'

Question: What we actually have to fear from killer robots

This news article should be represented to find a fitting news title

You’ve probably seen the latest Boston Dynamics video, which shows one of its recent quadruped creations, the SpotMini, opening a door despite being repeatedly accosted by a company employee. Boston Dynamics’ videos are notorious for eliciting both excitement and fear across social media and the internet. Nicholas King’s new parody of the Planet Earth documentary shows herds of SpotMinis taking over the planet. And the most recent season of Netflix’s Black Mirror features a murderous, highly autonomous SpotMini look-alike. So should we be concerned about killer robots taking over?
My take: I don’t expect the robot uprising anytime soon, but there’s plenty for us to worry about here — as a society, a culture, and a species.
The autonomous killer robots we imagine are so fearsome because (a) they’re autonomous, (b) they’re driven to kill, for some reason, and (c) they’re armed. Looking at these, in turn, allows us to isolate the true areas of concern and understand how we can work to head off our fears.
Autonomy
Autonomy is a layered, even nuanced concept. At the base level, autonomy can refer simply to the ability to get from A to B without human intervention.
When I see videos like the SpotMini demonstration, I immediately think back to my interview with Aaron Ames, professor of mechanical and civil engineering at Caltech, which focused on intelligent robots. Our discussion inevitably turned to the then-latest Boston Dynamics video which, at the time, featured the Atlas robot performing a backflip. Ames’ take on the level of autonomy involved essentially boiled down to: not much.
“It’s a preplanned behavior, so this robot has no knowledge of its environment, in the sense that it’s not observing where those blocks are and in real time adjusting its behavior and learning how to do this behavior,” said Ames. Rather, “they put those obstacles in the memory of the computer, they preplan those behaviors, [and] they do a bunch of experiments until they get the right behavior.”
In other words, there’s still lots of work to do before we see autonomously walking robots able to deftly navigate the real world. According to Ames, not only are we not there yet, but researchers don’t even agree on the right basic approach to get us there. Some, like Pieter Abbeel, advocate an approach based on end-to-end deep learning, while Ames suggests a more integrative approach.
So, for the time being, you can probably evade and outrun the robot, especially on varying terrain, but they’re getting there.
Agency
Still, autonomy in the sense of locomotion doesn’t quite get at what’s scary about the “autonomous killer robots” scenario. This is more about agency; the idea that the robot can have a beef with a human in the first place.
I can think of a few scenarios in which a robot would have it in for a human:
The robot is acting under its own volition, and it has decided that a particular offending individual needs to go. This implies some degree of general intelligence, goal-directedness, and intrinsic motivation. We’re very far from achieving this type of artificial intelligence, and don’t even really know how to define it. My interview with Greg Brockman explores this topic in detail. It seems quite premature to worry about this.
The robot kills a person as an unintended consequence of some human instruction that it’s following. This strikes me as more worthy of concern, especially given the general difficulty we have as humans with anticipating unintended consequences. And it’s what makes AI safety research so important. Check out my interview with Greg’s colleague Dario Amodei to hear about OpenAI’s work in this space.
The robot kills a person as an intended consequence of some human tasking. This is really the most likely near-term scenario, and thus one we should be most concerned about. Essentially the robot is a weapon, and its autonomy acts both as a potential multiplier on the amount of damage it can do and also, critically, so as to decouple any human from the ultimate taking of life.
I think it stands to reason that for the foreseeable future, the humans, as opposed to the robots, are the greater concern.
Armed
Accidents aside, what makes a killer robot a killer robot comes down to the fact that they were armed in the first place.
This seems like an inevitability that we’re quickly racing toward. Military robots already exist, and many governments are researching and developing more of them. According to Statista, global spending on military robotics was $6.9 billion dollars in 2015, and is expected to grow to $15 billion by 2025.
If you agree that the real risk of autonomous killer robots is when humans use them as weapons, and not because they’ve become self-aware, it seems natural that our best defense is to stop arming them.
It turns out that roboticists, ethicists, and AI researchers are already calling for the banning of weaponized autonomous robots. A number of organizations have formed around or taken up this cause, including the Human Rights Watch, the International Committee for Robot Arms Control, Article 36, and the Future of Life Institute, backed by Stephen Hawking, Elon Musk, and more.
So, back to our original question: Should we fear autonomous killer robots? To be honest, probably not. The chances that anyone reading this will perish at the hands of an autonomous killer robot is really, really, really small. But that doesn’t mean we shouldn’t be thinking about them and the many moral issues that they raise.
This story originally appeared in the This Week in Machine Learning & AI newsletter. Copyright 2018.
Sam Charrington is host of the podcast This Week in Machine Learning & AI (TWiML & AI) and founder of CloudPulse Strategies.

The editors of the prestigious Annals of Internal Medicine are urging their colleagues in the medical community to join the March for Science. To make sure they leave no room for doubt, the headline on their editorial reads, “Alternative Facts Have No Place in Science.”
Published by the American College of Physicians, it’s a jam-packed piece that explains how the politicization of science is threatening the health of our nation’s citizens.
So what, exactly, has made these physicians worked up enough to participate in Saturday’s march?
Let’s start with: Climate change is not a hoax ...
“Climate change has adverse effects on human health that include respiratory disease, heat-related conditions, vector-borne disease and food and water security.”
… and its effects are being felt, right here, right now.
“These are not merely future hypothetical threats in foreign lands — poor air quality due to global warming is already associated with poor respiratory health in U.S. locales.”
Also, vaccines work…
“Well-designed and meticulous studies [have established] the effectiveness and safety of vaccines for such diseases as measles, pertussis, varicella, and polio.”
… and anti-vaxxers are putting people in danger.
“…the antivaccine lobby is bolstered by political leaders who echo its ‘alternative facts’ about vaccines. Consequently, people are increasingly at risk for illness and death that vaccines had previously prevented.”
A 1-year-old girl is vaccinated against measles, mumps and rubella. Mel Melcon / Los Angeles Times A 1-year-old girl is vaccinated against measles, mumps and rubella. A 1-year-old girl is vaccinated against measles, mumps and rubella. (Mel Melcon / Los Angeles Times)
Guns don’t make people safer ...
“Growing evidence shows that guns do not make U.S. citizens safer but are actually associated with increased risk for suicide, homicide and injury.”
… and politicians don’t seem to care.
“Legislators ignore this evidence when they block regulatory actions that could enhance safety of firearms in our society.”
And then there’s Trump’s budget:
“The budget President Trump released in mid-March 2017 proposes to reduce the National Institutes of Health budget by $5.8 billion, an 18.3% reduction.”
Two scientists observe ocular tissue samples under a laser-scanning microscope at the National Eye I National Eye Institute, National Institutes of Health Two scientists observe ocular tissue samples under a laser-scanning microscope at the National Eye Institute, part of the National Institutes of Health. Two scientists observe ocular tissue samples under a laser-scanning microscope at the National Eye Institute, part of the National Institutes of Health. (National Eye Institute, National Institutes of Health)
They know it probably won’t go through, but …
“The proposed NIH cuts, along with the proposal to eliminate the Agency for Healthcare Research and Quality, exemplify that the administration fails or chooses not to recognize the importance of science to the health of the United States and its citizens.”
… and that could have long-term effects.
“Bright young people will be hesitant to pursue careers in medical research in such an environment, resulting in fewer people being ready to seek out what science can teach us to combat future problems.”
Good medicine can occur only thanks to good science.
“And good science cannot occur and its rewards cannot be reaped when we choose to pursue only the data and knowledge that seem to support our ideologies and denigrate the rest as ‘fake.’ Science doesn’t work that way.”
So get out there and make your voice heard.
Politicians who pick and choose the scientific data they are willing to promote and denigrate represent “a peril we must face head-on.”
Caption The Great American Eclipse The Great American Eclipse The Great American Eclipse Caption The Great American Eclipse The Great American Eclipse The Great American Eclipse Caption How do frog tongues work? New research from Georgia Tech reveals how frog tongues work. New research from Georgia Tech reveals how frog tongues work. Caption 2016 was Earth's third consecutive hottest year on record According to independent analyses by NASA and the National Oceanic and Atmospheric Administration, the 1.78-degree jump over the mid-20th-century average marks the third year in a row that global temperatures have reached record-shattering levels. According to independent analyses by NASA and the National Oceanic and Atmospheric Administration, the 1.78-degree jump over the mid-20th-century average marks the third year in a row that global temperatures have reached record-shattering levels. Caption LA 90: Explore the 'Jacuzzi of Despair,' a lake so salty it kills almost everything inside Underwater explorers discovered an underwater brine pool at the bottom of the Gulf of Mexico. The pit of super-salty water and dissolved methane kills any critter unlucky enough to fall inside. Underwater explorers discovered an underwater brine pool at the bottom of the Gulf of Mexico. The pit of super-salty water and dissolved methane kills any critter unlucky enough to fall inside. Caption Rosetta's last mission The European Space Agency's Rosetta orbiter will commit operational suicide early Friday morning, but first it has just a little bit more science to do. The European Space Agency's Rosetta orbiter will commit operational suicide early Friday morning, but first it has just a little bit more science to do.
deborah.netburn@latimes.com
Do you love science? I do! Follow me @DeborahNetburn and "like" Los Angeles Times Science & Health on Facebook.
MORE IN SCIENCE
What would make a computer biased? Learning a language spoken by humans
Type 2 diabetes, once considered a disease for adults, is increasingly common in tweens and teens
Saturn's moon Enceladus might have the right elements to sustain Earth-like life


Question: Represent the title to find an explanatory news article

Question: Coagulation Disorders Market to Register Steady Growth During 2018 - 2028

Represent the article to find a fitting news title

Coagulation disorder is a condition that affects the way blood normally clots. This clotting process is generally known as coagulation. For the blood to clot, the body requires certain proteins called clotting factors and blood cells called platelets. Normally, at the site of injured or damaged blood vessels, the clotting factors come together and form a fibrin clot. The clot helps in keeping the platelets in place and prevents the blood from flowing out. In people with coagulation disorders, the platelets or clotting factors don’t work the way they should or there’s a deficiency of clotting factors or platelets. When the blood doesn’t coagulate, it can lead to excessive or prolonged bleeding. Absence of the required number of platelets and clotting factors can also lead to sudden bleeding in the joints, muscles or other parts of the body. Majority of the coagulation disorders are inherited. However, some of the coagulation disorders may develop as a result of other medical conditions such as liver disease. Some of the common types of coagulation disorders are hemophilia A, hemophilia B, and Von Willebrand’s disease. The diagnosis requires various blood tests to be conducted such as Complete Blood Count (CBC) test and bleeding time test. The treatment of coagulation disorders vary depending on the type of bleeding and its severity. Though the treatment cannot cure coagulation disorders, they can help relieve the symptoms associated with it.
Factors Driving and Restraining the Coagulation Disorders Market
Government initiatives and an increase in healthcare expenditure have improved the quality of healthcare services. This has increase the demand for coagulation disorder test kits and treatments. Increase in the geriatric population will further drive the growth of coagulation disorders market. Increase in population has spurred the demand for diagnostic tests and treatments, this has spurred the growth of coagulation disorders market. However, high costs and risks associated with treatment and tests may have a negative impact on the coagulation disorders market. With technological advances these risks can be minimized. Stringent government regulations may also restrain the growth of coagulation disorders market.
Regional Outlook
The global market for coagulation disorders is segmented into North America, Latin America, Europe, Asia Pacific, Japan, and Middle East & Africa. North America leads the coagulation disorders market. Increasing number of coagulation disorder cases and high adoption rate for various tests and treatment are attributed to North America’s high market share. Northern Europe is the second large market for coagulation disorders. A steady rise in the demand for test kits and treatments have accelerated the growth of coagulation disorders in Eastern Europe. A surge in the number of coagulation disorder cases and increase in demand for various treatments fuel the growth of coagulation disorders market in Asia Pacific.
Competition Outlook
Examples of some of the key players in the coagulation disorders market are Bio-Rad Laboratories, Hoffman-La Roche Ltd., Griflos S.A., Abbott, Becton Dickinson, B Braun, Fresenius Kabi, Haemonetics Corporation, Immucor, Kidde-Fenwal and Macopharma,Quotient Limited, NOW Foods, Pure Micronutrients, Bayer AG, Nature’s Bounty Co., Sundown Naturals, Shaklee Corporation, MegaFood, Solgar Inc., Helena Laboratories, VitroScient, Guangzhou Wondfo Biotech, AB ANALITICA s.r.l. and Randox Laboratories
Request For Sample @https://www.futuremarketinsights.com/reports/sample/rep-gb-6888
Research Methodology
FMI utilizes a triangulation methodology that is primarily based on overall expenditure on life science research and R&D funding and capital equipment installed base to obtain precise market estimations and insights on life science and biotechnology associated products, technologies, applications and services. Bottom-up approach is always used to obtain insightful data for the specific country/regions. The country-specific data is again analysed to derive data at a global level. This methodology ensures high quality and accuracy of information.
Secondary research is used at the initial phase to identify the feasibility of the target products/technology categories and its respective segments, product and service offerings, equipment installed base in end use facilities, adoption rate and future impact of new technologies. Additionally, per capita consumption of kits, reagents and consumables among end users is tracked at a granular level to obtain the most accurate information. Each piece of information is eventually analysed during the entire research project which builds a strong base for the primary research information.
Primary research participants include demand-side respondents such as laboratory managers, procurement managers, research supervisors at academic and research institutes, as well as key opinion leaders in addition to supply-side respondents such as equipment and reagent manufacturers, custom solution and service providers who provide valuable insights on trends, research application of products and technologies, purchasing patterns, services offered and associated pricing.
Quantitative and qualitative assessment of basic factors driving demand, economic factors/cycles and growth rates and strategies utilized by key players in the market is analysed in detail while forecasting, in order to project year-on-year growth rates. These Y-o-Y growth projections are checked and aligned as per associated industry/product lifecycles and further utilized to develop market numbers at a holistic level.
Request For TOC @https://www.futuremarketinsights.com/toc/rep-gb-6888
On the other hand, we also analyse annual reports of various companies, investor presentations, SEC filings, 10k reports and earning call transcripts operating in the market to fetch substantial information about the market size, trends, opportunity, drivers, restraints and to analyse key players and their market shares. Key companies are segmented at tier-level based on their revenues, product portfolio and presence.
Please note that these are the partial steps that are being followed while developing the market size. Besides this, forecasting will be done based on our internal proprietary model which also uses different macro-economic factors such as overall life science research expenditure, R&D funding, industry based demand driving factors impacting the market and its forecast trends apart from other macroeconomic factors.

Represent this text to find a news title for it

DUBLIN, July 3, 2018 /PRNewswire/ --
The "Global Post-Traumatic Stress Disorder Therapeutics Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2018 To 2026" report has been added to ResearchAndMarkets.com's offering.
The global post-traumatic stress disorder therapeutics market is projected to reach US$ 10,679.5 Mn by 2026, expanding at a CAGR of 4.5% from 2018 to 2026. Antidepressants are the class of promising drugs that play a stellar role in the market.
Global post-traumatic stress disorder therapeutics market from 2018 to 2026 has been prepared based on exhaustive analysis with insights from industry professionals. The detailed study incorporates the market landscape and its growth scenarios for the forecast period from 2018 to 2026. To estimate the market size, the report ruminates branded, generic and pipeline drugs.
As per the U.S. National Comorbidity Survey Replication, around 6.8% individuals experience the ill effects of PTSD. As indicated by PTSD United, Inc. around 70% of individuals in the United States has encountered a few sorts of the shocking accident in any event once in their lives. This associate to around 223.4 million individuals.
The usage rate of healthcare services is highest in case of individuals suffering from PTSD. There are various symptoms that are commonly grouped into four different types: avoidance, changes in physical and emotional reactions, negative changes in thinking and mood, and intrusive memories that are identified in the individuals having post-traumatic stress disorder.
Based on the class of drug, the global post-traumatic stress disorder therapeutics market is segmented into antidepressants, anti-anxiety drugs, other drug classes (Alpha-1 & Alpha-2 Receptor Antagonists, Atypical Antipsychotics, and Anticonvulsants), and pipeline candidates. Rising prevalence of PTSD and the promising drug pipeline would additionally boost the post-traumatic stress disorder therapeutics market.
Geographically, the overall post-traumatic stress disorder therapeutics market is projected for the Middle East and Africa, Europe, North America, Latin America, and the Asia Pacific. North America currently drives the global market and projected to hold its supremacy throughout the forecast period.
However, Europe will be clearly challenged by the Asia Pacific by end of the forecast period. The need for post-traumatic stress disorder therapeutics drugs has become prominent in the Asia Pacific because of rapidly increasing events such as sexual assault, combats and inter-personal violence. There are massive chances for market penetration in countries like China, and India by the market leaders who at present have a stronghold in developed countries.
Key Topics Covered
Chapter 1. Preface
1.1. Report Description
1.1.1. Study Purpose
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2. Research Scope
1.3. Research Methodology
1.3.1. Phase I - Secondary Research
1.3.2. Phase II - Primary Research
1.3.3. Phase III - Expert Panel Review
1.3.4. Assumptions
Chapter 2. Executive Summary
2.1. Global Post-Traumatic Stress Disorder Therapeutics Market, by Drug Class, 2017 (US$ Mn)
2.2. Global Post-Traumatic Stress Disorder Therapeutics Market, by Geography, 2017 (US$ Mn)
Chapter 3. Global Post-Traumatic Stress Disorder Therapeutics Market Overview, 2016 - 2026 (US$ Mn)
3.1. Overview
3.2. Market Drivers
3.2.1. Growing Events of Violence and Wars
3.3. Challenges
3.3.1. Lack of Timely Diagnosis and Access to Care
3.3.2. Risk of Side Effects
3.4. Opportunities
3.4.1. Promising Pipeline Candidates
3.5. Attractive Investment Proposition, by Geography, 2017
3.6. Market Competition Assessment, 2017
Chapter 4. Global Post-Traumatic Stress Disorder Therapeutics Market, by Drug Class, 2016 - 2026 (US$ Mn)
4.1. Overview
4.2. Antidepressants
4.2.1. SSRIs
4.2.2. SNRIs
4.2.3. MAO Inhibitors
4.2.4. Tricyclic Antidepressants
4.3. Anti-anxiety Drugs
4.3.1. Beta-blockers
4.3.2. Benzodiazepines
4.4. Other Drug Classes
4.4.1. Alpha-1 & Alpha-2 Receptor Antagonists
4.4.2. Atypical Antipsychotics
4.4.3. Anticonvulsants
4.5. Pipeline Candidates (Qualitative Information)
4.5.1. SRX 246 (Phase II)
4.5.2. BNC 210 (Phase II)
4.5.3. Tonmya (Phase II)
Chapter 5. Global Post-Traumatic Stress Disorder Therapeutics Market, by Geography, 2016 - 2026 (US$ Mn)
5.1. Overview
5.2. North America
5.2.1. North America Post-Traumatic Stress Disorder Therapeutics Market, by Drug Class, 2016 - 2026 (US$ Mn)
5.2.2. North America Post-Traumatic Stress Disorder Antidepressants Market, by Type, 2016 - 2026 (US$ Mn)
5.2.3. North America Post-Traumatic Stress Disorder Anti-anxiety Drugs Market, by Type, 2016 - 2026 (US$ Mn)
5.2.4. North America Post-Traumatic Stress Disorder Therapeutics Market, by Other Drug Classes, 2016 - 2026 (US$ Mn)
5.2.5. North America Post-Traumatic Stress Disorder Therapeutics Market, by Country, 2016 - 2026 (US$ Mn)
5.2.5.1. U.S.
5.2.5.2. Canada
5.3. Europe
5.3.1. Europe Post-Traumatic Stress Disorder Therapeutics Market, by Drug Class, 2016 - 2026 (US$ Mn)
5.3.2. Europe Post-Traumatic Stress Disorder Antidepressants Market, by Type, 2016 - 2026 (US$ Mn)
5.3.3. Europe Post-Traumatic Stress Disorder Anti-anxiety Drugs Market, by Type, 2016 - 2026 (US$ Mn)
5.3.4. Europe Post-Traumatic Stress Disorder Therapeutics Market, by Other Drug Classes, 2016 - 2026 (US$ Mn)
5.3.5. Europe Post-Traumatic Stress Disorder Therapeutics Market, by Country, 2016 - 2026 (US$ Mn)
5.3.5.1. U.K.
5.3.5.2. Germany
5.3.5.3. Rest of Europe
5.4. Asia Pacific
5.4.1. Asia Pacific Post-Traumatic Stress Disorder Therapeutics Market, by Drug Class, 2016 - 2026 (US$ Mn)
5.4.2. Asia Pacific Post-Traumatic Stress Disorder Antidepressants Market, by Type, 2016 - 2026 (US$ Mn)
5.4.3. Asia Pacific Post-Traumatic Stress Disorder Anti-anxiety Drugs Market, by Type, 2016 - 2026 (US$ Mn)
5.4.4. Asia Pacific Post-Traumatic Stress Disorder Therapeutics Market, by Other Drug Classes, 2016 - 2026 (US$ Mn)
5.4.5. Asia Pacific Post-Traumatic Stress Disorder Therapeutics Market, by Country, 2016 - 2026 (US$ Mn)
5.4.5.1. Japan
5.4.5.2. China
5.4.5.3. Rest of APAC
5.5. Latin America
5.5.1. Latin America Post-Traumatic Stress Disorder Therapeutics Market, by Drug Class, 2016 - 2026 (US$ Mn)
5.5.2. Latin America Post-Traumatic Stress Disorder Antidepressants Market, by Type, 2016 - 2026 (US$ Mn)
5.5.3. Latin America Post-Traumatic Stress Disorder Anti-anxiety Drugs Market, by Type, 2016 - 2026 (US$ Mn)
5.5.4. Latin America Post-Traumatic Stress Disorder Therapeutics Market, by Other Drug Classes, 2016 - 2026 (US$ Mn)
5.5.5. Latin America Post-Traumatic Stress Disorder Therapeutics Market, by Country, 2016 - 2026 (US$ Mn)
5.5.5.1. Brazil
5.5.5.2. Mexico
5.5.5.3. Rest of Latin America
5.6. Middle East & Africa
5.6.1. Middle East & Africa (MEA) Post-Traumatic Stress Disorder Therapeutics Market, by Drug Class, 2016 - 2026 (US$ Mn)
5.6.2. Middle East & Africa (MEA) Post-Traumatic Stress Disorder Antidepressants Market, by Type, 2016 - 2026 (US$ Mn)
5.6.3. Middle East & Africa (MEA) Post-Traumatic Stress Disorder Anti-anxiety Drugs Market, by Type, 2016 - 2026 (US$ Mn)
5.6.4. Middle East & Africa (MEA) Post-Traumatic Stress Disorder Therapeutics Market, by Other Drug Classes, 2016 - 2026 (US$ Mn)
5.6.5. Middle East & Africa (MEA) Post-Traumatic Stress Disorder Therapeutics Market, by Region, 2016 - 2026 (US$ Mn)
5.6.5.1. GCC
5.6.5.2. Rest of MEA
Chapter 6. Company Profiles
6.1. Pfizer, Inc.
6.1.1. Business Description
6.1.2. Financial Information (Subject to data availability)
6.1.3. Product Portfolio
6.1.4. Key Developments
6.2. GlaxoSmithKline plc
6.3. Otsuka Pharmaceutical Co., Ltd
6.4. Novartis AG
6.5. AstraZeneca Plc
6.6. Azevan Pharmaceuticals, Inc.
6.7. Bionomics Ltd.
6.8. Tonix Pharmaceuticals Holding Corp.
6.9. Apotex, Inc.
For more information about this report visit
https://www.researchandmarkets.com/research/pn8bvk/global?w=5
Media Contact:
Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
View original content:http://www.prnewswire.com/news-releases/global-post-traumatic-stress-disorder-therapeutics-market-2018-2026-size-share-application-analysis-growth-trends-key-players-and-competitive-strategies-300675818.html
SOURCE Research and Markets


Question: represent the title to find an explanatory news article

Question: The Latest: 3rd judge blocks military transgender ban

SEATTLE (AP) — The Latest on courts blocking the president's efforts to keep transgender people from enlisting in the military (all times local):
5:20 p.m.
A third federal judge has blocked President Donald Trump's ban on transgender people joining the military.
U.S. District Judge Marsha Pechman issued her ruling Monday in a case brought by several plaintiffs, including a soldier based in Washington state and two young men who hope to enlist.
Washington Attorney General Bob Ferguson also intervened in the case to challenge Trump's policy.
Pechman found that the ban likely violates the plaintiffs' rights to due process and to equal protection under the law without advancing any government interest. She also said it would harm the state's efforts to protect its residents from discrimination.
Pechman blocked the government from imposing the ban pending further proceedings.
Judges in Maryland and Washington, D.C., also have ruled against the ban. It had been due to take effect Jan. 1.
___
8:10 a.m.
The Pentagon official tells The Associated Press that transgender people can enlist in the military beginning Jan. 1, despite President Donald Trump's opposition.
The new policy reflects growing legal pressure on the issue and the difficult hurdles the federal government would have to cross to enforce Trump's demand to ban transgender individuals from the military. Two federal courts already have ruled against the ban.
Potential transgender recruits will have to overcome a lengthy and strict set of physical, medical and mental conditions that make it possible, though difficult, for them to join the armed services.
Maj. David Eastburn says the enlistment of transgender recruits will start Jan. 1 and go on amid the legal battles. The Department of Defense also is studying the issue.

0:49 White House is 'keeping a close eye' on crisis at California's Oroville dam Pause
1:32 Press Secretary says press should focus more on leaks than Flynn's resignation
2:23 One arrest as protesters block DeVos from D.C. middle school
3:36 Treasury Secretary Mnuchin announces Venezuela sanctions
1:26 Who's at the door? Principal visiting homes of each of her 1,003 students
0:51 Trump administration eases Russian sanctions to allow U.S. tech exports
2:19 Warren: Shocked to find 'truth was out of order' on the Senate floor
0:46 Dozens rally at Tacoma's Northwest Detention Center after Seattle arrest
4:07 Federal judge temporarily halts Trump’s travel ban


Question: I found this news title. Can you represent it to find an explanatory news article?!

Question: Best Columbus Day Sales for Shoes & More

Summit by White Mountain Vivianne Italian leather sandal. Brand
With Columbus Day right around the corner (Monday), we’ve got sales on the brain.
Channel the spring ’18 runway and wear socks with sandals with the wedged style from Summit by White Mountain. It’s hard to say no when they’re marked down to $34 from their original price of $129.
Shop the Vivianne Italian leather sandal and more from brands like Coldwater Creek, H&M, Cole Haan and more.
And there’s plenty of other styles available for deep discounts, including sky-high sandals — like the pair above that bear a resemblance to Selena Gomez’s favorite Tod’s buckled wood platform style.
Summit by White Mountain
Dates: Oct. 6-12
Sale: Additional 20% off all sale shoes
Code at checkout: COLUMBUS20
Coldwater Creek
Dates: Oct. 6-10
Sale: Extra 40% off sales & outlet items (for a savings up to 75% off original prices)
Code at checkout: FALL40
Latigo
Date: Oct. 9
Sale: Free shipping
Code at checkout: None needed
Bernardo
Date: Oct. 9
Sale: Free two-day shipping
Code at checkout: DISCOVER
Baretraps
Date: Oct. 9
Sale: Free shipping
Code at checkout: None needed
Remo Tulliani
Date: Oct. 6-10
Sale: 25% off sitewide
Code at checkout: RTColumbus
Pikolinos
Dates of Sale: Oct. 6-9
Sale: Free gift with purchase
Code at checkout: COLUMBUS
Asos
Dates: Oct. 6-9
Sale: 50% off select items
Code at checkout: None needed
Urban Outfitters
Date: Oct. 6-9
Sale: 40% off sale items
Code at checkout: None needed
Yoox
Dates: Oct. 6-9
Sale: Up to 90% off sale styles
Code at checkout: no code needed
Bloomingdales
Dates: Oct. 6-9
Sale: Take 25% off a large selection of items
Code at checkout: FRIENDS
Macy’s
Dates: Oct. 4-9
Sale: Take 25% off
Code at checkout: STYLE
Cole Haan
Dates: Oct. 6-11
Sale: Take 30% off select items
Code at checkout: FALLEVENT
Sebago
Dates: Oct. 6-10
Sale: Take 50% off boat shoes
Code at checkout: 50OFF
Timberland
Dates: Oct. 6-11
Sale: 25% off select styles
Code at checkout: None needed
Banana Republic
Dates: Oct. 6-9
Sale: 40% off full-price items, extra 10% off sale items
Code at checkout: None needed
H&M
Dates: Oct. 7-9
Sale: Up to 60% off select items
Code at checkout: None needed

For the latest and best deals Like us at Facebook.com/DEALBOSS and follow us on Twitter @DEALBOSS.
There are four major shopping weekends left before Black Friday!
What? Seriously? It's not even summer yet!
I know, I know. But for the rest of 2018, we only have Memorial Day 2018 followed by July 4, Prime Day, the Labor Day shopping weekend and then Black Friday.
That means this weekend is pivotal for retailers hoping to gain your attention and increase sales. It's important to note that not all sales are created equal. While wireless earbuds (the top tech deal this week) are a fantastic purchase Memorial Day weekend, over-the-ear headphones aren't actually a deal until next week.
Click the play button to see what you should not buy this Memorial Day 2018. For a list of the best bargains, I have curated a full list of links and digital coupons below. Happy Savings!
1) $60 Off The Top Rated Cool Sleep Pillow In The Country For $39.99
2) $39.99 Weber Dual Probe Bluetooth Thermometer (Was: $60)
3) 50% Off Top Rated Wireless Bluetooth Self-Charging Sport Earphones
4) BOGO Vehicle Emergency Escape Tool + Car Smart Chargers For $29.99 (Was: $50)
5) $28.99 Summer Toy Box (and LED helicopters) Was: $50
6) Top Memorial Day BBQ & Grill Sale At Home Depot
7) $39.99 Amazon Echo Dots and Echo Alexa Deals
8) Up To 30% Off Patio Sets Starting At $99 At Target.com
9) Up To 40% Off Outdoor Serving Dishes At Walmart.com
10) Top Hotel & Flight Sale At Expedia.com
MORE FROM DEALBOSS!
Matt Granite is a freelance consumer reporter who produces stories and video for this Station, Amazon Live and others. He is not compensated by the brands featured here. This Station and its parent company may receive a share of the revenue from the site that sells the product if you purchase one of these products using the link on this page.
© 2018 TEGNA MEDIA


Question: Represent this title to get a news article that provides more details about it

Question: Singer Alanis Morissette loses millions in burglary at her LA home

The home of singer Alanis Morissette has been targeted by thieves who stole two million dollars (£1.6 million) worth of jewellery and other valuables.
The Los Angeles Police Department said it was investigating the burglary which happened in the upmarket Brentwood area on February 9.
A force spokesman said: "Suspects took a safe with about two million dollars worth of jewellery and other items inside.
"There was also some property damage."
Morissette, best known for her 1995 album Jagged Little Pill, is married to rapper Mario "Souleye" Treadway and the couple have two children together.
It is understood the family were not at home at the time of the burglary.
The incident comes a month after Morissette's former business manager admitted stealing more than seven million dollars (£5.7 million) from the singer and other celebrities.
Jonathan Todd Schwartz, 48, was charged wire fraud and subscribing to a false tax return for failing to disclose the embezzled funds to the tax authorities, US prosecutors said.
He admitted withdrawing about 4.8 million dollars of Morissette's money without her knowledge between May 2010 and January 2014.
When confronted about the missing funds, Schwartz said the money was an investment in illegal marijuana growing businesses, which he later admitted was false.
He has agreed to plead guilty to the offences in a plea deal with prosecutors, the US Department of Justice said.

Film executive Harvey Weinstein, who is embroiled in a sexual harassment controversy, has sold a home in Westport, Conn., for $1.65 million.
He bought the property more than two decades ago for $825,000, records show.
Built in 1953, the two-story residence sits on more than half an acre dotted with mature trees.
The 3,050-square-foot, whitewashed house opens in dramatic fashion to a living room with a wall of windows that take in the leafy grounds. The eat-in kitchen opens to a family room with a fireplace. The master suite has a sitting room and a private bath for a total of four bedrooms and three bathrooms.
The two-story home sits on more than half an acre in Westport, Conn. (Realtor.com) (Realtor.com)
Lawns, stone planters and mature landscaping fill out the grounds.
The property came up for sale in April for $2.25 million, records show. More recently it was listed for $1.795 million.
Darlene Letersky of Coldwell Banker Residential Brokerage was the listing agent, according to the Multiple Listing Service. Judy Michaelis, also with Coldwell Banker, represented the buyer.
Weinstein, 65, co-founded Miramax in 1979 and produced such hit films at the production company as “Shakespeare in Love” and “Chicago.” He founded his namesake studio, Weinstein Co., with his brother, Bob, in 2005.
In a statement to the Los Angeles Times on Thursday, the executive and producer apologized for behavior “with colleagues in the past [that] has caused a lot of pain.” He is taking a leave of absence from his studio to deal with his issues “head on.”
CAPTION Kid Rock recently sold his Balinese-inspired compound for $9.5 million, $2.1 million less than he paid for it in 2006, in a deal completed off-market. Kid Rock recently sold his Balinese-inspired compound for $9.5 million, $2.1 million less than he paid for it in 2006, in a deal completed off-market. CAPTION Kid Rock recently sold his Balinese-inspired compound for $9.5 million, $2.1 million less than he paid for it in 2006, in a deal completed off-market. Kid Rock recently sold his Balinese-inspired compound for $9.5 million, $2.1 million less than he paid for it in 2006, in a deal completed off-market. CAPTION The party-ready home in Marina del Rey is listed for sale at $3.799 million. The party-ready home in Marina del Rey is listed for sale at $3.799 million. CAPTION Actor Phillip P. Keene has a good reason for hanging out in the downstairs den of his Los Feliz home. Actor Phillip P. Keene has a good reason for hanging out in the downstairs den of his Los Feliz home. CAPTION The Tony winner's prized possession in this room is her Steinway, but she keeps other items there that also inspire her. The Tony winner's prized possession in this room is her Steinway, but she keeps other items there that also inspire her. CAPTION Jillian Michaels retreats to the office in her Malibu home when she needs some kid-free space. Jillian Michaels retreats to the office in her Malibu home when she needs some kid-free space.
neal.leitereg@latimes.com
Twitter: @LATHotProperty
MORE FROM HOT PROPERTY:
Beck lists refreshed Gerard Colcord home in Brentwood for $3.75 million
Cindy Crawford trims $10 million off the price of Malibu beach compound
President of Magic Johnson Enterprises snaps up a spot in Bel-Air
'General Hospital' producer puts Bel-Air estate up for lease or sale


Question: I found this news title. Can you represent it to find an explanatory news article?

Question: Derek and Hannah Jeter are Expecting a Baby Girl!

What is your favorite colo?
Thank you for voting.
You have already voted on this poll !
Please select an option !

Congrats are in order for Perrey Reeves!
The 47-year-old Entourage star and her husband, Aaron Endress-Fox, secretly welcomed their first child together, a baby girl, the actress' rep confirms to ET.
According to the rep, Phoenix Delphine Fox was born on Oct. 14, 2017.
Reeves and Fox became engaged in September 2014 and tied the knot on June 13, 2015. Although the two have yet to share a photo of their newborn, they certainly aren't shy about gushing over each other, or their two dogs, Rooster and Junip, via Instagram.
See some of their cutest posts below:
Happy New Year! Xx The Foxes A post shared by Perrey Reeves (@perreyreeves) on Jan 1, 2018 at 12:24pm PST
In more baby news, Khloe Kardashian is gearing up for the arrival of her first child. She and her boyfriend, NBA star Tristan Thompson, are expecting a baby girl, and the two couldn't be more ecstatic.
Kris Jenner told ET earlier this month at the grand opening of Paul Nassif's new MedSpa in Beverly Hills, California, that Kardashian plans to have two nurseries for her daughter. "Khloe's really excited and setting up two nurseries, one in Cleveland [where Thompson plays basketball] and one in Los Angeles," the momager explained.
Hear more in the video below!
Reporting by Brendon Geoffrion.
RELATED CONTENT:
Khloe Kardashian Excites Pregnant Eva Longoria by Gifting Her With Maternity Jeans
Pregnant Khloe Kardashian Poses Topless in New Photo Shoot -- See the Pics
Everything Khloe Kardashian Has Said About Her First Pregnancy
Related Gallery


Question: Represent this title to get a news article that provides more details about it.

Question: Poland Spring throws cold water on class-action lawsuit

Represent this text to find a news title for it.

PORTLAND, Maine (AP) — Poland Spring’s parent company on Friday asked a judge to dismiss a lawsuit that accuses the company of providing water that’s sourced from wells, not springs.
Stamford, Connecticut-based Nestle Waters North America contends the matter was already litigated in 2003 in Illinois and that a federal court can’t pre-empt a state court. That case ended with a $12 million settlement and Poland Spring continuing to tout “100 percent natural spring water.”
The corporate parent also says the plaintiffs should take up the matter with the Food and Drug Administration instead of turning to the courts.
The original lawsuit filed in Connecticut and a similar one in Maine contend the water that’s bottled by Poland Spring comes from wells or municipal sources, not the bubbling springs depicted on the label.
Poland Spring says its product meets the FDA’s definition that allows a bottling company to call its product “spring water” if it is drawn from the same source as a natural spring and meets certain requirements for chemical composition.
A letter from the state’s senior environmental hydrologist in August confirmed that all eight of Poland Spring’s water sources meet the FDA definition of spring water. The Maine Drinking Water Program implements the FDA rules governing spring water.
Alix Dunn, spokesperson for Nestle Waters, said consumers can be confident “in the accuracy of the labels on every bottle of Poland Spring.”
(Copyright (c) 2017 The Associated Press. All Rights Reserved. This material may not be published, broadcast, rewritten, or redistributed.)

Georgia special
The special election in Georgia to fill HHS Secretary Tom Price’s old congressional seat could end with a historic Democratic upset. The Sixth District seat has been held by a Republican continuously since Newt Gingrich won it in 1978, but changing demographics and what’s known as a “jungle primary” are giving Democrat Jon Ossoff a shot at winning today’s vote.
Georgia tea leaves
Spanning wealthier and Republican-leaning suburbs north of Atlanta, Tom Price’s old seat is just the kind of place Democrats would love to pull off an upset. They’d point to it as evidence of excitement in their base, and support from the upper-income Republicans and college graduates who eluded them in 2016. But winning will be tough. We look at data from the 50,000 early votes already cast to gauge the contest.
Custody battle
A lawyer for conservative radio show host Alex Jones says his client is nothing more than a showman. He said it in a Texas court, where Jones is fighting for custody of his children. His ex-wife argues the views and conspiracy theories on Jones’ radio show prove he’s unfit for fatherhood.
Silver lining
Whatever your feelings about tax day, retailers want you to know they feel your pain (or relief). The tax day freebie has become something of a modern tradition as corporations angle for new customers. Here’s a sampling of the companies trying to take some sting out of today by offering big discounts and free stuff.
Church cops
Alabama lawmakers could send a bill to the governor this week that would allow a megachurch to establish its own police force. The bill has already passed the state Senate and is awaiting a House vote. We take a look at why the plan is getting mixed reactions.
Corn sole
Reebok is creating its first shoe made entirely from biological materials. The shoe, available this fall, will have a cotton upper and a sole made from Susterra, a corn-based plastic substitute. It’s intended to be completely compostable, and will even use biologically derived glue to join the pieces together.
More top news:
U.S.
Supreme Court turns back Arkansas bid for execution spree
Young woman falls to death from balcony near college campus
Man accused of stealing more than 100 phones at Coachella
World
Trump congratulates Turkish leader on vote as observers cry foul
Dozens killed as bus plunges into mountain ravine
New details on North Korea’s failed missile test
Politics
North Korea forces Trump off his campaign provinces
Ivanka Trump’s company flourishing as she starts White House job
Democrats nationwide eye Georgia special election
Ethics experts say Trump admin. is least transparent in decades
Business
This could be the year of falling rents
How boomers are adjusting to prospects of frugal retirement
Health
How to pick the right allergy medicine for kids
7th-grader tests cancer fighting chemicals in green tea
Science and tech
Saturn’s moon Titan may have “electric sand”
Millions of likes lost in Facebook’s user purge
Entertainment
Harvey Weinstein on his plans to fight Trump


Question: Represent this title to get a news article that provides more details about it

Question: जज्बे और परहेज से हारा कैंसर

Represent this text to find a news title for it

Read the latest and breaking Hindi news on amarujala.com. Get live Hindi news about India and the World from politics, sports, bollywood, business, cities, lifestyle, astrology, spirituality, jobs and much more. Register with amarujala.com to get all the latest Hindi news updates as they happen.

अहमदाबाद। पहले चरण के मतदान के बाद गुजरात में चुनावी प्रचार तेज हो गया है। सोमवार को पीएम मोदी ने पाटन की चुनावी रैली के दौरान कांग्रेस पर हमला बोला।
पीएम मोदी ने रैली के दौरान कहा कि पहले चरण में कांग्रेस की हार तय है, इसलिए वे इवीएम का बहाना लेकर आरोप लगा रहे हैं। इसके अलावा उन्होंने गुजरात के गांवों में जाकर लोगों के बीच बच्चों की शिक्षा के प्रति जागरुकता जगाने की बात कही। साथ ही कांग्रेस की कमियों की ओर भी इशारा किया।
पीएम ने कहा, जब हम किसानों के पास गए, कृषि महोत्‍सव किया, हम अमीरों की मदद के लिए नहीं गए थे। हम गरीबों के बीच गए। दुखद है कि कांग्रेस नेताओं का जन्‍म सोने के चम्‍मच के साथ हुआ है, इसलिए वे कभी नहीं समझ पाएंगे कि गरीबी क्‍या है।
When we went to the farmers, did Krishi Mahotsav, we did not go out helping the rich. We went among the poor. Sadly, Congress leaders born with golden spoons will never understand what poverty is: PM Narendra Modi in Patan #GujaratElection2017 pic.twitter.com/6qW7yoOAAz
During peak summer, I would go to the villages of Gujarat and ask parents to educate their children. Whose children were they? Were they Ambani's children? No. They were children of the poor. We are working for poor: PM Narendra Modi in Patan #GujaratElection2017 pic.twitter.com/4P2K3QoY8y
— ANI (@ANI) 11 December 2017


Question: I found this news title. Can you represent it to find an explanatory news article?

Question: Art Zuidema out as London city manager

There was a major late-night shake up at London city hall as council announced Art Zuidema is no longer with the city following a five-year stint as City Manager.
City treasurer Martin Hayward has been appointed acting city manager, council announced in a brief media release issued at 12:03 a.m. on Wednesday.
Sometimes in a professional relationship there is a time to part ways. I wish Mr. Zuidema all the best in his future endeavours. — Tanya Park (@tanneramma) February 15, 2017
“Sometimes in a professional relationship there is a time to part ways. I wish Mr. Zuidema all the best in his future endeavours,” tweeted councillor Tanya Park.
In the release, council also thanked Zuidema for his leadership during the last five years.
More information to come.

represent this text to find a news title for it

1:07 Blues defenseman Alex Pietrangelo prepares for NHL Winter Classic Pause
1:20 Blues forward David Perron talks about the NHL Winter Classic
1:46 Hall of Famer Chris Pronger returns to the ice for Winter Classic Alumni Game
6:57 How to slice an onion without crying, and other kitchen knife skills
2:41 Kristen Poshard talks about personal tragedy and her new position with Madison County
0:44 Lebanon public library plans expansion
1:13 It's a girl! First local baby of the new year born at St. Elizabeth's
1:07 Edwardsville football coach talks playoff loss to Glenbard West
2:00 Estes, Thomas connect to give East St. Louis playoff win


Question: Represent the title to find an explanatory news article

Question: 'Unkindness Of Ghosts' transposes the plantation's cruelty to the stars

Rivers Solomon's An Unkindness of Ghosts is the kind of novel I need to describe in terms of what it did to me. Reading it, I felt it carving out a vastness inside me, pouring itself into me like so many stars, and the more I read the bigger I felt, falling down a rabbit-hole of sky and wanting only to go deeper and farther with every page.
Aster lives on a generation ship called Matilda, organized much like an antebellum plantation in space: The black and brown people on the lower decks, tightly policed by vicious guards and overseers, do the hard labor that enables the white people in the upper decks to hoard wealth, heat, and comfort. The upperdeckers also hoard religion; their Sovereignty, a sort of limited constitutional monarchy, claims that every sin committed by lowdeckers widens the gulf between Matilda and the Promised Land they've been in search of for 325 years.
Orphaned as an infant by her mother's suicide, neuroatypical, and ambiguously gendered among those who hold to rigid binaries, Aster is an outsider to most of her social groups: Her bunkmates mock her and her fellow lowdeckers are confused by her. In spite of her differences, she's respected for the extensive medical knowledge she's gleaned from her dead mother's journals, and for her curious friendship with an upperdecker who's almost as much of an anomaly as she is: Theo, the Surgeon General, a light-skinned bastard son of the former Sovereign. With his support, and using the resources of a secret greenhouse she calls her botanarium, Aster navigates Matilda's horrors to bring succour and healing where she can.
But there's something wrong with Matilda's power source — something connected to the current ailing Sovereign, and more importantly, to Aster's lost mother, Lune. With her sometimes-friend, sometimes-antagonist Giselle's help, Aster begins decoding Lune's journals to trace the mystery of her mother's death and the secrets at Matilda's heart.
To name a thing Solomon does in this book is to praise it. I loved the way each deck had its own dialect, how lowdeckers explored those differences with each other and learned each other's languages. I loved the attention to gender variance, to queerness, and the rooting of rigidity around gender in the ruling class' obsession with policing black bodies. I loved the exploration, in several heartbreaking scenes, of how enslavement breeds cruelty along an intersecting circuitry of lines among lowdeckers, as everyone tries their best to survive. I loved the clarity and precision of the prose, which felt like drinking cool water on an empty stomach, like being limned in light on the inside. Most of all, though, I loved Aster's voice, Aster's perspective on the world, Aster's anger and her fierce, unrelenting kindness to those she loves, no matter how they hurt her.
When I finished An Unkindness of Ghosts and put it down, I almost immediately picked it up again to re-read from the beginning, to admire how early certain seeds were sown, how thoroughly integrated were its plantation roots into space-faring soil. This book is not an allegory for life on plantations: it's a transposition, and through it an interrogation, an investigation, of the falsehoods and broken memories of a nightmare past. It drags up pervasive stereotypes of happy mammies and consenting love between slaver and enslaved and vivisects them, the dextrous voices of characters like Aint Melusine and Giselle deployed like scalpels to part the inflamed skin of bad history.
I sometimes hated an overseer so much that I had to put the book down to imagine all the ways in which I wanted him to die. I picked it up again to see Aster and Giselle imagining the same things.
What Solomon achieves with this debut — the sharpness, the depth, the precision — puts me in mind of a syringe full of stars. I want to say about this book, its only imperfection is that it ended. But that might give the wrong impression: that it is a happy book, a book that makes a body feel good. It is not a happy book. I love it like I love food, I love it for what it did to me, I love it for having made me feel stronger and more sure in a nightmare world, but it is not a happy book. It is an antidote to poison. It is inoculation against pervasive, enduring disease. Like a vaccine, it is briefly painful, leaves a lingering soreness, but armors you from the inside out.
Amal El-Mohtar is the Hugo Award-winning author of The Honey Month and the editor of Goblin Fruit, an online poetry magazine.

Filmmaker Derek Chiu mines a controversial slice of Hong Kong history for a sadly current and universal drama about political resistance and its personal toll.
Read More


Question: I found this news title. Can you represent it to find an explanatory news article?

Question: Lin-Manuel Miranda Debuts All-Star Charity Song ‘Almost Like Praying’

Lin-Manuel Miranda has recruited an all-star lineup for his new track “Almost Like Praying.”
Related: Lin-Manuel Miranda Unveils “Immigrants” Video
Marc Anthony, Ruben Blades, Camila Cabello, Pedro Capo, Dessa, Gloria Estefan, Fat Joe, Luis Fonsi, Juan Luis Guerra, Alex Lacamoire, John Leguizamo, Jennifer Lopez, Rita Moreno, Ednita Nazario, Joell Ortiz, Anthony Ramos, Gina Rodriguez, Gilberto Santa Rosa, PJ Sin Suela, Tommy Torres, and Ana Villafañe are all featured on the new song, which will raise money for hurricane relief in Puerto Rico.
Written by Miranda only last week, the original song borrows its title and instantly indelible hook from the classic show tune “Maria,” from West Side Story.
Check out the star-studded charity single below.

This news article should be represented to find a fitting news title

Whoa.. a bit too freaky for me! #AGT
RELATED CONTENT
WATCH: America’s Got Talent Golden Buzzer #1
Check Out How This Kindergarten Class Starts Each Day
Halsey Had To Be Treated By Medics At Her Show
ABC Has Cancelled “Roseanne” After Racist Tweet
WATCH: Man Scales The Side Of A Building To Save A Child Dangling From A Balcony
WATCH: An Interviewer Told Taylor Swift She Needed To Take A Shower…And Her Fans Do NOT Like It!


Question: Represent this title to get a news article that provides more details about it

Question: Using epigenetics to help the immune system fight ovarian cancer

Immunotherapy, a cancer treatment approach that’s decades old, has become the hottest subject in oncology. In the past few years, researchers have developed a host of new drugs capable of jumpstarting the immune response to tumors. Now, these treatments have reached the clinic. Reports on their success were the focus of numerous presentations at this summer’s American Society for Clinical Oncology (ASCO) conference in Chicago. In naming immunotherapy its Advance of the Year for 2016, ASCO President Julie Vose, M.D., said “no recent advance has been more transformative.” In media reports, other physicians have said immunotherapy could be “an even more important intervention than chemotherapy,” and patients have chronicled “miracle” results.
“Cancer patients who respond to immunotherapy tend to have a prolonged response,” says Rebecca Arend, M.D., an assistant professor in the UAB Division of Gynecologic Oncology and associate scientist in the Experimental Therapeutics Program at the UAB Comprehensive Cancer Center who specializes in treating ovarian cancer. “It’s really exciting, because this is something that we don’t usually see with chemotherapy and 75 percent of patients recur within two years of receiving initial chemotherapy and surgery for ovarian cancer.” Unfortunately, only a fraction of patients benefit from immunotherapy treatments. So Arend, with a new grant from UAB’s Center for Clinical and Translational Science, is exploring a fresh approach: “priming” the body to respond to immunotherapy using another new class of drugs: epigenetic modifiers.
“Cancer patients who respond to immunotherapy tend to have a prolonged response. It’s really exciting, because this is something we don’t usually see with chemotherapy.” Unfortunately, only a fraction of patients currently see benefit from immunotherapy treatments.
A loophole in the body’s defenses
There are many varieties of immunotherapy, including checkpoint inhibitors, CAR T cell therapy, therapeutic cancer vaccines and oncolytic viruses. But they all begin with the concept that the immune system is very good at isolating and destroying unhealthy cells. The trouble is, tumors often develop mutations that let them escape these attacks by switching off or otherwise thwarting the immune response. Immunotherapies work to get the body’s defense system back into the fight.
The greatest excitement at the moment surrounds the new class of checkpoint inhibitors, including PD-1 and CTLA-4 inhibitors. “Your body has a natural response of putting the brakes on the immune system,” says Arend. “These drugs take those brakes off.”
Why is the immune system braking in the face of a grave threat like cancer? Some years ago, researchers realized that T cells, the immune system’s frontline soldiers, are often found surrounding tumors. But instead of attacking the malignant cells, or calling in other troops, they aren’t doing much of anything. That’s because the tumor cells have co-opted the T cells’ on-off switch. They have to have one: Without a “stop” sign, T cells would keep on attacking, chewing into healthy tissue and causing serious damage. So they have several different kinds of checkpoint receptors to receive “stand-down” messages from healthy cells in the area. But cancer cells know how to send these messages, too, blunting the immune response. The discovery of these checkpoints, and the development of drugs to block them, has brought immunotherapy to the fore in cancer care.
The most well-known of the checkpoint inhibitors, pembrolizumab (Keytruda), is a PD-1 inhibitor. It was initially approved by the FDA in 2014 to treat advanced melanoma, but it has been used successfully to treat several other cancers, including non-small cell lung cancer and head and neck cancer. Former President Jimmy Carter credited the drug with shrinking his brain tumors and saving his life. Other patients have experienced similarly striking results. But many more do not. In one study of a different checkpoint inhibitor, targeting CTLA–4, a fifth of patients with metastatic melanoma experienced durable remissions.
“Mutation burden enhances the response to immunotherapy, probably because the tumor looks even more like non-self. So more and more research is being done to look at ways that we can prime tumors to look like the ones in these good responders.”
Mutations could hold the key
What’s the difference between responders and non-responders? Recent studies have shown that a key factor could be the mutation burden of a patient’s tumor. All cancers are triggered by mutations, but the number of mutations varies widely. “Mutation burden enhances the response to immunotherapy, probably because the tumor looks even more like non-self,” says Arend. “So more and more research is being done to look at ways that we can prime tumors to look like the ones in these good responders.”
Several human trials are already underway using epigenome-modifying drugs in combination with checkpoint inhibitors. There are several theories as to why the combination of epigenetic and immunotherapy drugs is more successful than either alone. “One theory is that epigenetic drugs enhance immune modulator pathways,” Arend says. “Another is that you are causing more genomic disarray in the tumor itself. And there are papers that have shown that resistance to immunotherapy is because of epigenetic modification. So there could be multiple interactions.”
Arend and others also suspect that the timing and dosage of the combination will be critical to success. “Most of the human trials that are ongoing basically give the drugs at the same time,” Arend says. “I don’t know that that’s the way to go. It may be that you need to give the epigenetic drug first, followed by immunotherapy. And it may be more beneficial to give it upfront, rather than later on in the course of disease.”
The right drug, for the right patient, at the right time
Arend hopes to gain new insight into these questions thanks to a Multidisciplinary Pilot Program Award from the UAB CCTS. With the award, one of nine given by the CCTS in 2016, Arend will study the immunotherapy/epigenetic drug combination in laboratory models of ovarian cancer, and in a potential human clinical trial. The Pilot Program grants offer up to $60,000 to cover one year of research into an emerging, high-potential problem.
Arend notes that she has been working under the mentorship of Cancer Center senior scientist Donald Buchsbaum, Ph.D., since her first year as a fellow at UAB. She is partially funded by a training scholarship through the American Board of Obstetrics and Gynecology (ABOG) Education Foundation. Her collaborators on this research include Troy Randall, Ph.D., J. Claude Bennett Professor of Medicine in the UAB Division of Clinical Immunology and Rheumatology, who is an expert in immune signaling in cancer; and Sara Cooper, Ph.D., investigator at Huntsville’s HudsonAlpha Institute for Biotechnology, who is studying genomic profiling to predict drug response in ovarian cancer. (In 2014, the UAB Comprehensive Cancer Center and HudsonAlpha launched a consortium to combine research efforts at the institutions.) The research team will be studying two types of epigenetic drugs – DNA methyltransferase inhibitors and histone deacetylase inhibitors – in combination with an immunotherapy drug, a PD1 inhibitor.
In a separate project, Arend is collaborating with Cooper “to fine-tune the process of prescribing medications for ovarian cancer patients with specific genetic signatures,” she says. Arend is also working with HudsonAlpha scientists to study the immune repertoire (subtypes of immune proteins) found in T cell receptors. “We’re sequencing the RNA of T cell receptors as a possible marker of response to PD1 therapy,” Arend says.
Personalized medicine is a major interest for Arend. “I’m a clinician-scientist,” she says. “I give the chemotherapy and I also study new treatments in the lab. I want to understand which patients are going to respond to which drugs, and why.”

Represent this text to find a news title for it!

This article is sponsored by the Israel Cancer Research Fund.
Cancer is the second-leading cause of death in the United States, responsible for 22.5 percent of American fatalities. Only heart disease is more deadly.
In Israel, cancer is the No. 1 killer. That’s partly why Israel has become a research leader in the fight against the disease.
Many of the world’s most effective cancer treatments have roots in Israeli research, sometimes going back decades. The work taking place in Israeli labs today may lead to lifesaving treatments years in the future.
Here are five promising areas Israeli researchers are studying in their quest for better cancer detection and treatment. Together they provide a glimpse into the remarkable scope of cancer research being conducted by internationally renowned scientists across Israeli institutions.
Mutant reeducation camp and the fight against ovarian cancer
Mutant reeducation may sound like the plot of the next “X-Men” movie, but for a team of Israeli researchers it could be central to finding new treatments for ovarian cancer, an especially deadly disease because of the difficulties of early detection. This year, 22,440 women in America will be diagnosed with ovarian cancer and 14,080 will die from it, according to American Cancer Society estimates.
In a program at Israel’s Weizmann Institute of Science financed in part by the Israel Cancer Research Fund, Dr. Varda Rotter is looking for ways to fight the disease on the molecular level using a protein known as the “king of tumor suppressors.”
The protein, p53, stops the formation of tumors. But when p53 mutates, it makes cancer cells more malignant and boosts their resistance to drugs.
Rotter and her team have identified a small number of molecules that are able to “reeducate” mutant p53 and restore it to its role scanning for damaged DNA and stopping the development of tumors. They are also looking for methods to reeducate the mutant p53 to fight and eradicate mutant cells.
“We are trying to find a way to convert or reeducate the mutant p53 to its role as the ‘guardian of the genome,’” Rotter said. “It will reeducate the p53 into the right type of p53 and will show that under such circumstances there is a reduction of cell death in treated cells.”
Rotter hopes her team’s research will result in methods that can be applied along with immunotherapy to give women with ovarian cancer a better chance of beating the disease.
Restoring infertility? Hit the restart button.
For many cancer patients, surviving is just the first part of the battle. They often face serious lifelong problems, such as infertility or the loss of healthy tissue that is highly difficult to regrow.
“How do you replace damaged body parts?” asked Dr. Jacob Hanna of the Weizmann Institute.
The key, Hanna and many others believe, lies in stem cells. Stem cells are early-stage cells that are capable of dividing into infinitely more cells and have the potential to become different cell types, such as bone, skin or muscle. Stem cells can help repair damaged tissue.
Hanna is using ICRF funding to research ways to take cells from healthy areas of the patient’s body and turn them back into induced embryonic stem cells — the equivalent of the first cells with which each human body begins. Because the stem cells in Hanna’s model would come directly from the patient’s DNA rather than from a donor, the tissue would not face rejection.
Reverting the cells to their beginning state would be “like hitting the restart button of your computer,” Hanna said.
The treatment would be unique. Currently the only proven stem-cell therapy in use is centered on transplanting bone marrow. There are no stem-cell-based treatments for replacing organs or tissue other than blood. But Hanna believes stem-cell treatments are going to become reality in the next 20 years, and restoring fertility to infertile cancer survivors could be one major benefit.
“We want to make mature human cells in the Petri dish,” Hanna said. “If this is successful, it could be a major breakthrough for solving infertility problems in general, not only for women who underwent chemotherapy.”
For example, scientists could make an unlimited supply of female eggs by growing stem cells in a dish and freezing them.
“This could stop doctors from avoiding doing chemotherapy because they’re worried about damaging the patient’s fertility,” Hanna said. “It would allow them to give longer treatment or stronger regiments.”
To fight brain cancer, think small. Very, very small.
Glioblastoma, a particularly aggressive and deadly form of brain cancer, carries a very grim prognosis: Patients have a median survival time of about 15 months from the day of discovery.
Tel Aviv University researcher Dr. Dan Peer is seeking ways to fight brain tumors using a targeted nanoparticle platform to transport drugs directly to the sites that need treatment rather than a more general chemotherapy or surgery. Targeted treatments the size of a nanometer – a millionth of a millimeter — would minimize the effects on the rest of the body by targeting only the cancer cells and avoiding healthy cells nearby.
The delivery vehicle would be RNA — ribonucleic acid, whose main role is to carry instructions from DNA. It is one of the three major biological macromolecules essential for all forms of life, along with DNA and proteins. By binding the RNA to a nanoparticle platform, researchers hope to bypass the hurdles that usually thwart drug delivery by specifically targeting the problem areas of the tumor.
“The fact that nanomedicine can get around many of the obstacles that hinder drug delivery could mean a greater quality of life and life expectancy for patients suffering from highly deadly forms of cancer like glioblastoma,” Peer said.
He and his colleagues are also using their ICRF research grant to examine ways to design drugs suited to a patient’s specific genetic profile and then develop appropriate nanoparticle delivery vehicles.
By carrying the drugs specifically to the cancer cells and not to the healthy ones, the treatment will have fewer adverse effects and toxicities for the patient while maximizing the drugs’ therapeutic effect.
“If we can somehow diminish the spreading of the tumor and improve diagnosis and therapeutic effect,” Peer said, “that will be beneficial for the patient.”
Fighting carcinomas: Rehab for non-malignant cells
We’ve all had moments in life that spark our survival instincts under stress. Humans aren’t the only ones that use chemical processes to survive stressful situations.
To survive high fevers, for example, organisms as small as cells deploy the “heat-shock response” — activating proteins called chaperones that help cells maintain their structure and not melt down in the event of high temperatures. Tumors, too, use the heat-shock response to increase their odds of survival and grow ever-more malignant.
For tumors to expand and metastasize, they “recruit” non-malignant cells in the tumor microenvironment and get them to work for them and help them evade the immune system. Dr. Ruth Scherz-Shouval of the Weizmann Institute is studying the tumor microenvironment to determine how the non-cancerous cells get reprogrammed to act against the body and support the tumor rather than defend the body against the tumorous growth.
“The cells of the microenvironment don’t have the mutation that causes cancer cells to become cancer cells – yet they do things they are not supposed to do,” she said. “We are interested in understanding how this happens.”
Scherz-Shouval compared treatment in the microenvironment to rehabilitating a nonviolent offender who can still be put on the right path — unlike a hardened felon (the tumorous cell) who is too far gone to save. Think rehab for non-malignant cells.
The research is relevant to solid tumors and specifically to carcinomas — a cancer arising in skin tissue or the lining of internal organs. Scherz-Shouval has found a correlation between the heat-shock response and poor patient survival in late-stage breast and lung cancer.
She hopes her research, backed by the ICRF, will lead to a more generalized way to target cells in the microenvironment that will complement current cancer treatments and give patients a better chance at recovery.
Wanted: A better way to fight leukemia
Israel has the fourth-highest per capita rate of leukemia deaths worldwide. In America, leukemia kills more than 24,000 people per year.
Most leukemia treatments today focus on chemotherapy, steroid drugs and stem-cell transplants. But Ben-Gurion University of the Negev researcher Roi Gazit is on the hunt for more effective, targeted treatments.
“Immune therapies and stem-cells treatments offer great advantages but too many options to choose from,” Gazit said. “Our models will help to better specify which treatment may suit a specific type, and even sub-type, of the disease. Unfortunately, there is no one-size-fits-all treatment for leukemia. That’s why we need tailor-made models to fit the treatment to the disease.”
Gazit is focusing on how to develop targeted treatment of cancer cells using hematopoietic stem cells — stem cells used in cancer treatment because of their ability to divide and form new and different kinds of blood cells.
The research involves taking primary cells — cells cultured directly from a subject — and turning them into malignant leukemia growth inside mice. By examining how the leukemia develops, Gazit is exploring ways that hematopoietic stem cells may be deployed to arrest the leukemia.
The research models his lab is using, part of a project supported by the Israel Cancer Research Fund, could help scientists develop more types of immunotherapy and more ways to use stem cells to combat leukemia.
“With any new information we can gain better understanding, which translates into better treatment,” Gazit said.
(This article was sponsored by and produced in partnership with the Israel Cancer Research Fund, whose ongoing support of these and other Israeli scientists’ work goes a long way toward ensuring that their efforts will have important and lasting impact in the global fight against cancer. This article was produced by JTA’s native content team.)